Bristol Myers Squibb To Highlight More Than 80 Abstracts At ASH ...

Từ khóa » Cc-92480-mm-003

• A Study To Determine The Recommended Dose And ... - Clinical Trials

• A Safety, PK And Efficacy Study Of CC-92480 Monotherapy And In ...

• Phase I Trial Supports CC-92480 For Heavily Pretreated Myeloma

• CELMoD CC-92480/Dexamethasone Combo Shows Early Activity In ...

• Mezigdomide - Bristol-Myers Squibb - AdisInsight - Springer

• Novel Non-Immunologic Agents For Relapsed And Refractory ... - NCBI

• Promising Therapeutic Approaches For Relapsed/refractory Multiple ...

• The Changing Landscape Of Relapsed And/or Refractory Multiple ...

• Aiding Early Clinical Drug Development By Elucidation Of The ...

• Treatment Options For Patients With Heavily Pretreated Relapsed ...

• [PDF] Developing Next Generation Immunomodulatory Drugs And Their ...

• CC-92480 Shows Encouraging Efficacy In First-in-Human Study For ...

• Multiple Myeloma Clinical Trials In Georgia